Treatment of Parkinson's disease with proglumide, a CCK antagonist.
Proglumide, a cholecystokinin antagonist, did not improve Parkinson's disease in a preliminary drug treatment trial.
Piolti
R
R
Department of Neurology, School of Medicine, University of Milan, Italy.
Appollonio
I
I
Cocco
E
E
Ferrarese
C
C
Frattola
L
L
Rovati
L
L
Panerai
A E
AE
D000368:Aged; D002766:Cholecystokinin / Q000037:antagonists & inhibitors; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D011377:Proglumide / Q000627:therapeutic use*
D007980:Levodopa; D002766:Cholecystokinin; D011377:Proglumide